[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acquired-hemophilia-a\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acquired-hemophilia-a":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,37],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100551549","a-survey-of-susoctocog-alfa-genetical-recombination-in-participants-with-acquired-haemophilia-a-100551549",false,"NCT06461533","A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A","General Use-results Survey of OBIZUR for I.V. Injection (All-case Surveillance)","Inclusion Criteria:\n\n\\- All participants with Acquired Haemophilia A, treated with Susoctocog Alfa (Genetical Recombination).\n\nExclusion Criteria:\n\n\\- None","ALL",{"count":18,"type":19},25,"ESTIMATED","OBSERVATIONAL","This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.\n\nThe main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA.\n\nDuring the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).",[23],"Acquired Hemophilia A","RECRUITING","2026-08-05",{"date":27,"type":28},"2026-08-07","ACTUAL",{"date":30,"type":28},"2024-06-10",{"date":32,"type":19},"2028-05-31",{"name":34,"class":35},"Takeda","INDUSTRY",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":47,"conditions":48,"keywords":49,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},"100558420","a-study-of-obizur-in-adults-with-acquired-hemophilia-a-aha-in-south-korea-100558420","NCT06550882","A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea","Post-Marketing Surveillance (Use-result Surveillance) of OBIZUR Injection [Susoctocog Alpha (Porcine Antihemophilic Factor VIII, Recombinant)] for the Approved Indications in South Korea","Inclusion Criteria:\n\n* Participants with AHA.\n* Participants who are determined to have the clinical need to receive Obizur treatment.\n* Participants aged 18 years or older at time of initiation of Obizur treatment.\n* Participants agreed to participate in the study and voluntarily signed the informed consent.\n\nExclusion Criteria:\n\n* Participants with hypersensitivity to any of the components of this drug.\n* Participants with Congenital Hemophilia A with Inhibitors (CHAWI).\n* Participants for whom Obizur treatment is contraindicated as per product label.\n* Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.","18 Years",{"count":46,"type":19},9,"Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.\n\nThe main aim of the study is to learn how safe OBIZUR is in adults with AHA.\n\nOther aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting.\n\nThe treatment of the participants will be determined by the treating physicians.\n\nDuring the study, data already existing in the participants' medical record and new data will be collected.",[23],[50],"Drug Therapy","2026-05-15",{"date":53,"type":28},"2026-05-19",{"date":55,"type":28},"2025-07-22",{"date":57,"type":19},"2026-09-30",{"name":34,"class":35},4]